Search Results

You are looking at 1 - 10 of 40 items for :

  • "accelerated phase" x
  • Refine by Access: All x
Clear All
Full access

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz, and Meir Wetzler

occur in the transition from chronic to accelerated phase. 2 Most cases of CML in the United States are diagnosed in the chronic phase. Untreated CML typically progresses from chronic phase through an accelerated phase at a median of approximately 4

Full access

An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse

Scott M. Lindhorst, Richard D. Lopez, and Ronald D. Sanders

chronic phase, accelerated phase, or blast crisis Discuss treatment strategies and monitoring of response to isolated CNS disease in patients with CML Many effective therapeutic options are available for patients with chronic myelogenous leukemia

Full access

Treatment Milestones in Chronic Myelogenous Leukemia: Stay the Course or Change Therapy?

Jerald P. Radich

with chronic-phase disease from progressing to accelerated phase/blast crisis. “There is a point of no return in CML biology,” he declared ( Figure 1 ). In fact, most cases of progression to accelerated phase/blast crisis in the IRIS trial occurred

Full access

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Neil P. Shah, Ravi Bhatia, Jessica K. Altman, Maria Amaya, Kebede H. Begna, Ellin Berman, Onyee Chan, Joan Clements, Robert H. Collins Jr, Peter T. Curtin, Daniel J. DeAngelo, Michael Drazer, Lori Maness, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Vivian Oehler, Keith Pratz, Iskra Pusic, Michal G. Rose, William Shomali, B. Douglas Smith, Michael Styler, Moshe Talpaz, Tiffany N. Tanaka, Srinivas Tantravahi, James Thompson, Steven Tsai, Jennifer Vaughn, Jeanna Welborn, David T. Yang, Hema Sundar, and Kristina Gregory

eventually progress to accelerated phase CML (AP-CML) or blast phase CML (BP-CML) in 3 to 5 years on average. 5 Progression to AP-CML and BP-CML bridges a continuum of clinical features (ie, fever, bone pain, spleen size), cytogenetic changes, and blast

Full access

Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2005, an estimated 4,600 cases will be diagnosed, and 850 patients will die of the disease. The median age of disease onset is 53 years; however, CML occurs in all age groups, with an increasing proportion of younger patients in more recent series. ML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients. Several definitions of the accelerated phase of the disease are summarized.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2003, an estimated 4,300 cases will be diagnosed, and 1,700 patients will die from the disease. The median age of patients with the disease is 53, but CML occurs in all age groups, with an increasing proportion of younger patients in more recent studies. CML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Management of Advanced-Phase Chronic Myelogenous Leukemia

Jerald P. Radich

accelerated phase and blast crisis vary, the prime factor is blast count, according to Dr. Radich. In most clinical trials, accelerated phase is between 15% and 29% blasts in blood or marrow, with blast crisis being more than 30% blasts in blood and marrow

Full access

Monitoring Molecular Response to Tyrosine Kinase Therapy in Chronic Myelogenous Leukemia

Jerald P. Radich

in preventing transformation of disease to accelerated phase/blast crisis, he added. However, in terms of long-term outcomes such as overall and progression-free survivals, Dr. Radich revealed that none of the second-generation agents has proved to

Full access

Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management

Presented by: Gabriela S. Hobbs and Christopher Bell

-generation BCR::ABL TKI, is approved for use in chronic phase and accelerated phase CML, with starting doses of 400 and 600 mg, respectively. According to Dr. Bell, however, imatinib is not typically used in accelerated phase CML, because other agents are

Full access

Chronic Myelogenous Leukemia, Version 1.2015

Susan O’Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Vishnu VB. Reddy, Neil P. Shah, B. Douglas Smith, David S. Snyder, Meir Wetzler, Kristina Gregory, and Hema Sundar

expression profiling has shown a close correlation of gene expression between accelerated phase CML (AP-CML) and blast phase CML (BP-CML). The bulk of the genetic changes in progression occur in the transition from CP-CML to AP-CML. 6 The activation of the β